Eli Lilly's obesity drug Mounjaro is 'more efficacious and more tolerable' than competitors: Analyst

Evan Seigerman, BMO Capital Markets Managing Director of BioPharma Equity Research, joins Yahoo Finance Live to discuss why investors are becoming bullish on weight-loss drug opportunities and the outlook for the manufacturers.